AbstractChaired by Dr Zoe Nilsson, Global Product Marketing Manager, bit.bio email@example.com
1. Luckshman Jeremy Anton
Talk title: high throughput screening using stem cell derived neurons
Take home points:
i. Drug discovery for neurodegenerative diseases are often limited by the inability to source cell lines that correctly exhibit disease phenotype in an endogenous manner
ii. Stem cells are able to provide disease relevant models for testing that are scalable and can be differentiated into the appropriate tissue type
iii. Direct reprogramming of stem cells may allow for faster, more efficient differentiation and shows increased robustness in HTS assays compared to traditional differentiation techniques
Talk title: Using iPSC-derived cells to explore mitochondrial disease
Take home points:
i. Diseases caused by mutations of mitochondrial DNA (mtDNA) are devastating multisystem disorders with highly variable presentations. They are very poorly understood and no disease modifying treatments are available.
ii. Because we can’t manipulate the mitochondrial genome, we can’t readily generate animal or cell based models and so these diseases have been very hard to study.
iii. We are using iPSc’s derived from patient fibroblasts, differentiated into neurons and muscle to study the pathophysiology in the cells most severely affected by the disease, with the ultimate goal of identifying novel therapeutic targets for these otherwise intractable diseases.
Use of stem cell technology has the potential to transform our understanding of these hitherto obscure and difficult diseases.
Talk Title: Printing synthetic, living and hybrid materials
Take home points from the presentation
i. By 3D printing, we have assembled functional synthetic tissues comprising patterned networks of thousands of aqueous droplets joined by lipid bilayers
ii. A related printing technology has been used to pattern a variety of living cells, providing structures that include small tumours and neural tissues
iii. Millimeter-scale printed structures can be used as building blocks for cm-scale structures ranging from synthetic axons to hybrid constructs containing both synthetic and living cells